These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29503555)

  • 1. Tanezumab: a selective humanized mAb for chronic lower back pain.
    Webb MP; Helander EM; Menard BL; Urman RD; Kaye AD
    Ther Clin Risk Manag; 2018; 14():361-367. PubMed ID: 29503555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
    Patel MK; Kaye AD; Urman RD
    J Anaesthesiol Clin Pharmacol; 2018; 34(1):111-116. PubMed ID: 29643634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tanezumab for the treatment of osteoarthritis pain.
    Gondal FR; Bilal J; Kent Kwoh C
    Drugs Today (Barc); 2022 Apr; 58(4):187-200. PubMed ID: 35412532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.
    Leite VF; Buehler AM; El Abd O; Benyamin RM; Pimentel DC; Chen J; Hsing WT; Mazloomdoost D; Amadera JE
    Pain Physician; 2014; 17(1):E45-60. PubMed ID: 24452657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
    Cattaneo A
    Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tanezumab in the treatment of chronic musculoskeletal conditions.
    Jayabalan P; Schnitzer TJ
    Expert Opin Biol Ther; 2017 Feb; 17(2):245-254. PubMed ID: 27936977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
    Gimbel JS; Kivitz AJ; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2014 Sep; 155(9):1793-1801. PubMed ID: 24937440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.
    Walicke PA; Hefti F; Bales R; Lu SP; Ruckle JL; Brown MT; West CR; Shelton DL
    Pain Rep; 2018 May; 3(3):e653. PubMed ID: 29922745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain.
    Bimonte S; Cascella M; Forte CA; Esposito G; Cuomo A
    J Pain Res; 2021; 14():1959-1967. PubMed ID: 34234542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
    Konno SI; Nikaido T; Markman JD; Ohta M; Machida T; Isogawa N; Yoshimatsu H; Viktrup L; Brown MT; West CR; Verburg KM
    Pain Manag; 2022 Apr; 12(3):323-335. PubMed ID: 34786956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.
    Abdiche YN; Malashock DS; Pons J
    Protein Sci; 2008 Aug; 17(8):1326-35. PubMed ID: 18505735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-nerve growth factor in pain management: current evidence.
    Chang DS; Hsu E; Hottinger DG; Cohen SP
    J Pain Res; 2016; 9():373-83. PubMed ID: 27354823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials.
    Lian J; Wang J; Li X; Yang S; Li H; Zhong Y; Gao H; Chen G
    Clin Neuropharmacol; 2023 Jan-Feb 01; 46(1):6-16. PubMed ID: 36542785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
    Bannwarth B; Kostine M
    Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome.
    Nickel JC; Atkinson G; Krieger JN; Mills IW; Pontari M; Shoskes DA; Crook TJ
    Urology; 2012 Nov; 80(5):1105-10. PubMed ID: 23010344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.